ARRIVE Essential 10

1. Study design: Methods, Animals, paragraph 2 (Line 57-66).

2. Sample size: Methods, Animals, paragraph 2 (Line 63-66).

3. Inclusion and exclusion criteria: NA

4. Randomisation: Methods, Surgery procedures, paragraph 3 (Line 84-85).

5. Blinding: NA

6. Outcome measures：Methods,Clinical measurements, paragraph 1 (PI, GI and PD) (Line 95-97);

Methods, PICF sampling and processing and Enzyme-linked immunosorbent

assay (ELISA) analysis, paragraph 1 (PICF, TNF-α and IL-1β) (Line 103-104,

107-108);

Methods, Histopathological analysis, paragraph 2 (early inflammatory

infiltration) (Line 128-130).

7. Statistical methods：Methods，Statistical analysis，paragraph 1 (Line 135-138).

8. Experimental animals: Methods, Animals, paragraph 1 (Line 54-56).

9. Experimental procedures: Methods, Surgery procedures, Clinical measurements, PICF sampling and processing, Enzyme-linked immunosorbent assay analysis, Histopathological analysis (Line 74-333).

10. Results：Results, Clinical findings, Histological observations and histomorphometrical measurements (Line 140-175).

ARRIVE Recommended Set

11. Abstract: Line 1-17

12. Background：Line 19-48

13. Objective：Abstract, paragraph 3 (Line 43-48)

14：Ethical statement：Methods, paragraph 1(Line 51-52)

15. Housing and husbandry: Methods, Animals, paragraph 1 (Line 55-56)

16. Animal care and monitoring：Methods, Animals, paragraph 1 (Line 56-57)

17. Interpretation/scientific implications：Conclusion, paragraph 1 (Line239-241)

18. Generalizability/translation: Conclusion, paragraph 1 (Line239-241)

19. Protocol registration: Declarations, Funding, (Line 258-260)

20. Data access：Declarations (Line263)

21. Declaration of interests: Declarations, Funding, (Line 258-260)